Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/41019
Full metadata record
DC FieldValueLanguage
dc.contributor.authorParra Carrillo, J.Z.
dc.contributor.authorFernandez, M.
dc.contributor.authorBarrera, M.
dc.contributor.authorBahena, J.
dc.contributor.authorEstrella, M.
dc.contributor.authorOlivares Ruiz, R.
dc.contributor.authorLepe, L.
dc.contributor.authorArriaga, R.
dc.contributor.authorBonilla, C.
dc.contributor.authorFonseca, S.
dc.contributor.authorMiranda, S.
dc.contributor.authorSegovia, C.
dc.contributor.authorGarcía Luna Viesca, M.D.C.
dc.date.accessioned2015-09-15T17:49:10Z-
dc.date.available2015-09-15T17:49:10Z-
dc.date.issued2004
dc.identifier.urihttp://hdl.handle.net/20.500.12104/41019-
dc.identifier.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-10344242919&partnerID=40&md5=0f12e5bf1b649728636d05a349df2fa7
dc.identifier.urihttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15617453
dc.description.abstractBlood pressure is not adequately controlled in almost 50% of patients with hypertension who are in receipt of antihypertensive therapy. This multicentre, prospective, open-label trial was designed to determine whether or not once-daily telmisartan 80 mg reduced blood pressure during the last 6 h of the 24-h dosing interval in patients with mild-to-moderate hypertension who were unresponsive to previous antihypertensive therapy. The study comprised 100 patients (47 males, 53 females) who had failed to respond satisfactorily to prior treatment given for a minimum of 3 months. At screening, 24-h ambulatory blood pressure monitoring (ABPM) was conducted after the patient had been treated with the currently prescribed antihypertensive medication. Following 5 weeks of telmisartan 80 mg treatment, ABPM was repeated. Telmisartan significantly reduced mean systolic blood pressure, diastolic blood pressure (DBP) and pulse pressure compared with previous antihypertensive therapy over each time interval (24-h, morning, night-time and the last 6 h of the dosing interval [2.00 a.m.-8.00 a.m.]) analysed. In addition, more than 90% of patients responded successfully (clinic DBP <90 mmHg or a >10 mmHg reduction in clinic DBP) at the end of telmisartan treatment. In conclusion, telmisartan provides effective blood pressure control throughout the 24-h dosing interval in patients with mild-to-moderate hypertension who were unresponsive to previous antihypertensive medication.
dc.relation.isreferencedbyScopus
dc.relation.isreferencedbyWOS
dc.relation.isreferencedbyMEDLINE
dc.titleEffect of telmisartan 80 mg once daily on 24-h blood pressure profile in patients with mild-to-moderate hypertension failing to respond to prior antihypertensive therapy
dc.typeArticle
dc.relation.ispartofjournalInternational Journal of Clinical Practice, Supplement
dc.relation.ispartofissue145
dc.relation.ispartofpage9
dc.relation.ispartofpage15
dc.subject.keywordAmbulatory blood pressure monitoring; Angiotensin II receptor blocker; Antihypertensives; Hypertension; Telmisartan / Index Medicus;Adolescent;Adult;Aged;Angiotensin II Type 1 Receptor Blockers/ad [Administration & Dosage];Angiotensin-Converting Enzyme Inhibitors/ad [Administration & Dosage];Antihypertensive Agents/ad [Administration & Dosage];Benzimidazoles/ad [Administration & Dosage];Benzoates/ad [Administration & Dosage];Blood Pressure/ph [Physiology];Female;Humans;Hypertension/dt [Drug Therapy];Hypertension/pp [Physiopathology];Male;Middle Aged;Prospective Studies;Treatment Outcome
dc.contributor.affiliationParra Carrillo, J.Z., Inst. de Invest. Cardiovascular, Universidad de Guadalajara, Hospital Civil Dr. Juan I. Menchaca, Guadalajara, Mexico, Salvador Quevedo y Zubieta, 750 Col. Independencia, Guadalajara, Jal. CP 44340, Mexico; Fernández, M., Clinica de Hipertension, Inst. Natl. Nutr./Cie. Med. S. Z., México City, Mexico; Barrera, M., Clínica Mérida, Mérida, Yucatán, Mexico; Bahena, J., Servicio de Cardiología, Hospital Universitario de Monterrey, Nuevo León, Mexico; Estrella, M., Servicio de Cardiología, Hospital Universitario de Monterrey, Nuevo León, Mexico; Olivares Ruiz, R., Hospital Valentin Gomez Farias, ISSSTE Guadalajara, Jalisco, Mexico; Lepe, L., Servicio de Cardiología, Centro Medico Nacional La Raza, IMSS, México City, Mexico; Arriaga, R., Hospital de Cardiología, Ctro. Medico National Siglo XXI IMSS, México City, Mexico; Bonilla, C., Inst. de Invest. Cardiovascular, Universidad de Guadalajara, Hospital Civil Dr. Juan I. Menchaca, Guadalajara, Mexico; Fonseca, S., Inst. de Invest. Cardiovascular, Universidad de Guadalajara, Hospital Civil Dr. Juan I. Menchaca, Guadalajara, Mexico; Miranda, S., Medical Department, Boehringer Ingelheim Promeco, México, Mexico; Segovia, C., Medical Department, Boehringer Ingelheim Promeco, México, Mexico; García Luna Viesca, M.D.C., Medical Department, Boehringer Ingelheim Promeco, México, Mexico
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.